Hims & Hers Health, Inc. ( (HIMS) ) has released its Q3 earnings. Here is a breakdown of the information Hims & Hers Health, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hims & Hers Health, Inc. is a leading health and wellness platform that offers personalized care solutions to enhance the well-being of individuals globally. The company operates primarily in the health and wellness sector, providing accessible healthcare services through its innovative online platform.
In its third-quarter 2025 financial results, Hims & Hers Health, Inc. reported a significant increase in revenue, reaching nearly $600 million, marking a 49% growth compared to the previous year. The company also achieved a net income of approximately $16 million and an adjusted EBITDA of over $78 million, showcasing strong financial performance and operational efficiency.
Key highlights from the earnings report include a 21% year-over-year growth in subscribers, reaching almost 2.5 million, and a 19% increase in monthly online revenue per average subscriber. The company also narrowed its full-year 2025 revenue guidance to between $2.335 billion and $2.355 billion, with adjusted EBITDA expected to be between $307 million and $317 million. Additionally, Hims & Hers is in discussions with Novo Nordisk to potentially offer Wegovy injections through its platform, expanding consumer options.
Looking ahead, Hims & Hers Health, Inc. remains optimistic about its growth trajectory, supported by a strong balance sheet and strategic investments. The company is focused on broadening access to personalized care and is confident in its ability to meet its ambitious long-term targets, reflecting a positive outlook for future performance.